The National Cholesterol Education Program made several changes to its adult treatment panel report on the detection, evaluation and treatment of high blood cholesterol.
The National Cholesterol Education Program made several changes to its adult treatment panel report on the detection, evaluation and treatment of high blood cholesterol.
The revised guidelines recommend that physicians increase emphasis on coronary heart disease risk status as the guide to the type and intensity of cholesterol-lowering therapy. Patients with evident coronary heart disease are at highest risk and a therapeutic goal of low-density lipoproteins of less than 100 mg/dL is recommended. Age (45 years or older for men, and 55 years or older for women) was added to the list of major risk factors.
The guidelines recommend that physicians delay the use of drug therapy in most young men 35 years and younger and in pre-menopausal women with moderately high low-density lipoproteins (160 mg/dL to 220 mg/dL) who are otherwise at low risk for coronary heart disease. However, the guidelines encourage physicians to consider high-risk, post-menopausal women and high-risk elderly with high blood cholesterol as candidates for drug therapy.
The guidelines also urge physicians to pay more attention to low high-density lipoprotein levels as coronary heart disease risk factors. Physicians should add high-density lipoprotein levels to initial cholesterol-screening tests and evaluate them when selecting drug therapy. The guidelines designate a high high-density lipoprotein level as a factor that reduces the risk of coronary heart disease.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.